Sponsor pipeline

ProDa BioTech, LLC clinical trial pipeline

Get alerts when ProDa BioTech, LLC's trials change

2 active trials 2 recruiting 3 disease areas 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days

2026-09-01
Primary completion pushed: 2026-07-01 → 2027-07-01
Completion pushed: 2026-10-01 → 2027-10-01
NCT06460298 ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative… · Phase 1/2

Active trials by phase

Phase 1
1
Phase 1/2
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1/2
NCT06460298 ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative… Triple Negative Breast Cancer Recruiting 2026-08-31
Phase 1
NCT06182072 ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting 2025-10-01

Disease areas by active trials

Breast Cancer (1) · Pancreatic Cancer (1) · Triple-Negative Breast Cancer (1)

Get alerts when ProDa BioTech, LLC's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free